NR3C2 and myocardial infarction: Several breakthroughs have been made to reduce HF due to MI, such as administering angiotensin-converting enzyme (ACE) inhibitors, β-receptor blocking agents, and aldosterone receptor antagonists, but the prevalence of HF in MI patients is still high [5, 6].